

## Title

### Colorectal cancer treatments

Reference Number: RDF2388-24

Date of Response: 21/03/24

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

*In the past 3 months, how many patients have been treated for Colorectal Cancer [CRC] with the following regimens? If possible, please also provide the split of metastatic vs non-metastatic patients for each regimen.*

REGIMEN	TOTAL PATIENTS	METASTATIC PATIENTS	NON-METASTATIC PATIENTS
Capecitabine	21	*<5	20
CAPIRI	7	7	0
CAPOX	40	17	23
Cetuximab with FOLFIRI	15	15	0
Cetuximab with FOLFOX	0	0	0
Cetuximab as a single agent	0	0	0
Cetuximab with Encorafenib	*<5	*<5	0
Irinotecan as a single agent	*<5	*<5	0
FOLFIRI	0	0	0
FOLFOX	0	0	0
Fluorouracil (5FU) as a single agent	0	0	0
Oxaliplatin as a single agent	0	0	0
Nivolumab with Ipilimumab	*<5	*<5	0
Panitumumab with FOLFIRI	7	7	0
Panitumumab with FOLFOX	*<5	1	0
Panitumumab as a single agent	0	0	0
Pembrolizumab	6	6	0
Any other systemic anti-cancer therapy	39	30	9
Palliative care only*	46		46

\*<5 - Section 40 (2)

Please note that in accordance with Section 40 (2) where activity is 5 or less than 5, the Trust is unable to provide the exact information. We consider the data exempt on the following grounds:

The Trust considers that disclosure of the information risks identifying individuals.

The reason for this is that the number of patients for which this applies is very low.

This and the fact that the data requested relates to the RDUH Health NHS Trust only and therefore relates to patients treated in a specific location (rather than covering a larger geographical area), increases the risk of identification or self-identification.

The Trust's view is that s.40(2) is applicable because disclosure of information which could lead to a patient being identified would be a breach of the patient's rights under the Data Protection Act Data Protection Principles set out in Schedule 1 of the GDPR, namely Principle 1.